This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Should You Invest in the State Street Health Care Select Sector SPDR ETF ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
ETFs to Play as Investors Chase Diversification Amid Tech Rout
by Yashwardhan Jain
From "software-mageddon" to rising AI capex pressuring Big Tech, diversification via defensive and global ETFs gains focus.
U.S. Consumer Confidence Slumps to Decade Low: ETF Areas to Play
by Sanghamitra Saha
U.S. consumer confidence hits a decade low. Defensive, quality & dividend ETFs like XLP, XLV, XLU, SPHQ & VYM may offer shelter.
Healthcare ETFs in Focus as UnitedHealth Rises 4% Post Mixed Q4 Results
by Aparajita Dutta
Healthcare ETFs draw attention as UNH climbs 4% on mixed Q4 results, a better 2026 cost outlook, and rising concerns over Medicaid pressure.
3 Healthcare ETFs to Buy as Flat Medicare Rate Proposal Hits Insurers
by Aparajita Dutta
Flat Medicare Advantage rate hikes hit insurers hard, but diversified healthcare ETFs may help investors weather the policy shock.
ETFs to Buy Post JNJ's Q4 Earnings Surprise & Bullish Cash Flow View
by Aparajita Dutta
JNJ beat Q4 earnings and sales estimates and sees 2026 free cash flow rising to $21B, making healthcare ETFs a safer way to play its momentum.
December Jobs Data Put Focus on These Sector ETFs & Stocks
by Sanghamitra Saha
December jobs data highlight sector shifts as healthcare and restaurants add jobs, while retail lags. ETFs XLV, EATZ in focus.
Betting on a Boom: 3 Healthcare ETFs for 2026 and Beyond
by Aparajita Dutta
After a late-2025 rebound eased policy fears, healthcare ETFs like IXJ are gaining attention as investors position for a sector comeback in 2026.
Spotlight on Health ETFs as NVO & LLY Cut Obesity Drug Price in China
by Aparajita Dutta
Novo Nordisk cuts Wegovy prices in China, which may shift investor focus toward diversified healthcare ETFs.
Bet on These Top-Ranked Healthcare ETFs Before 2025 Ends
by Aparajita Dutta
XLV and similar healthcare ETFs are gaining momentum as strength in biotech, increased AI adoption, and rising defensive demand position the sector for year-end leadership.